Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Title | Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Bisbinas I., Katsarou A., Filippaios A., & Mantzoros C. S. |
Journal | Osteoporos Int |
Volume | 25 |
Issue | 5 |
Pagination | 1633-42 |
Date Published | 2014 May |
ISSN | 1433-2965 |
Keywords | Absorptiometry, Photon, Aged, Antibodies, Monoclonal, Humanized, Biomarkers, Body Mass Index, Bone Density, Bone Density Conservation Agents, Case-Control Studies, Creatinine, Denosumab, Female, Femur Neck, Fibronectins, Humans, Lumbar Vertebrae, Middle Aged, Osteoporosis, Postmenopausal, Osteoporotic Fractures, Parathyroid Hormone, Teriparatide |
Abstract | UNLABELLED: In vitro data suggest that myokine irisin may affect bone metabolism by promoting osteoblast differentiation while inhibiting osteoclast differentiation. In this study, circulating irisin levels were associated with previous osteoporotic fractures but not with bone mass and were not affected by denosumab or teriparatide treatment for 3 months. |
DOI | 10.1007/s00198-014-2673-x |
Alternate Journal | Osteoporos Int |
PubMed ID | 24599275 |